Abstract Body

Even in the era of widespread ART, HIV-associated talaromycosis is still common in endemic areas globally. Current guidelines recommend liposomal amphotericin B as the preferred induction therapy, but liposomal amphotericin B is not available in certain settings. Induction therapy with amphotericin B deoxycholate or voriconazole has been shown to be effective treatments for talaromycosis. However, prospective clinical trials comparing these two drugs are absent from the literature

In this open-labelled, multicenter, prospective controlled trial, we enrolled patients at 17 hospitals in China from 2019 to 2020. A total of 359 patients received treatment with either intravenous amphotericin B deoxycholate or voriconazole. Each individual was invited to participate in a 48-week follow-up. The primary end point was all-cause mortality during the first 2 weeks after baseline. Secondary end points were mortality at week 48, clinical resolution of talaromycosis, fungal clearance at week 2, and the development of the immune reconstitution inflammatory syndrome (IRIS).

We observed no difference in the risk of death at weeks 2 or at week 48 after multivariable logistic regression and multivariable Cox proportional-hazards modelling. Logistic regression analysis revealed a significantly lower odds ratio of clinical resolution (aOR=0.543, 95% CI: 0.338-0.872) and fungal clearance (aOR= 0.605, 95% CI: 0.377-0.972) over the course of 2 weeks in voriconazole users than in amphotericin B deoxycholate users. A higher number of patients in the amphotericin B deoxycholate group than in the voriconazole group had hemoglobin levels <74 g/L (p=0.015) and potassium levels <2.4 mmol/liter (p=0.009).

Induction therapy using voriconazole had a similar efficacy in terms of all-cause mortality rate to induction therapy using amphotericin B deoxycholate in HIV-infected patients with talaromycosis over a 48-week observation period. Amphotericin B deoxycholate contributed to earlier fungal clearance and clinical resolution of symptoms, but was more likely to develop myelosuppression and hypokalemia. In contrast, voriconazole had fewer adverse effects than amphotericin B deoxycholate, but seemed less effective in clinical resolution and fungal clearance.